Digital Asset DirectEmpower Clinics Inc.
Contact Details Proactive Canada Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com Company Website https://www.proactiveinvestors.ca/
December 20, 2022 03:20 AM Pacific Standard Time
Video
News ReleaseThe Chicago School of Professional Psychology
Studies show that by February, 80 percent of New Year’s resolutions have been abandoned. So how do you make sure yours are among the 20 percent that are kept longer than a couple of months? Psychologists say it’s important to focus not on the goal but on the process of change. New Year’s resolutions often fail because they encourage a goal-oriented, rather than a process-oriented approach. It’s not about achieving a single goal, it’s about developing a habit or set of habits that result in the desired goal(s). “The process of change starts with understanding that a behavior is producing negative consequences,” says Dr. Michele Nealon, Psy.D., President of The Chicago School of Professional Psychology. “Then comes the internal negotiation—evaluating the pros and cons of changing. When you decide to change, then comes preparation, and this is critical—set yourself up for success.” “Next, decide your action steps and how you plan to maintain or modify these steps over time,” she adds. “Finally, plan for falling off the wagon—and get right back on track.” According to Dr. Nealon, this process can take weeks or months, so that is another reason why New Year’s resolutions often don’t work. “It’s difficult to wake up one day and suddenly decide you will change a long-held habit or practice,” she says. “Better to give yourself some time to think over the entire process and make sure that you are committed to change." She offers five tips for increasing chances of successful change include: Make change actionable and measurable Create a plan for incremental change; taking small steps to start Challenge yourself to be accountable or find an accountability partner Be forgiving; when you inevitably fall off the wagon, get back up About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu
December 19, 2022 09:00 AM Pacific Standard Time
News ReleaseHong Kong Baptist University
HONG KONG SAR - Media OutReach - 19 December 2022 - A research team led by Hong Kong Baptist University (HKBU) has identified a molecular target for bone anabolic therapies using a selected aptamer that serves as an inhibitor of sclerostin, a protein that prevents bone growth. The discovery offers hope for the development of an effective next-generation treatment for osteoporosis and osteogenesis imperfecta that is free of cardiovascular risk compared to the marketed antibody drug. The research findings have been published in the international academic journals Nature Communications and Theranostics. The New drug is at the pre-clinical trial development stage, and the research team plans to start clinical trials in the US and on the Mainland in 2024. Current medication increases cardiovascular risk Osteoporosis is a metabolic condition which leads to a reduction in bone density, resulting in weakened bones that are more fragile and likely to break. O steogenesis imperfecta, also known as “brittle bone disease”, is a rare congenital genetic disorder characterised by extremely fragile bones. Sclerostin has been identified as a therapeutic target for both diseases. In 2019, the US Food and Drug Administration (FDA) approved the use of the monoclonal antibody against sclerostin for the treatment of postmenopausal osteoporosis. Studies have also shown that sclerostin antibody enhances bone mass and bone strength of mice with osteogenesis imperfecta. However, as sclerostin plays a protective role in the cardiovascular system, it was seen that sclerostin antibody increased the risk of heart attacks, stroke and cardiovascular death during clinical trials. Therefore, a black box warning for potential cardiovascular risks is required by FDA. A research team led by Professor Lyu Aiping, Dr. Kennedy Y.H. Wong Endowed Professor in Chinese Medicineand Director of the Institute of Integrated Bioinformedicine and Translational Science at HKBU; Professor Zhang Ge, Director of the Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases at HKBU; and Dr Yu Yuanyuan, Manager of the Guangdong-Hong Kong-Macau Greater Bay Area International Research Platform for Aptamer-based Translational Medicine and Drug Discovery and Assistant Professor of the School of Chinese Medicine at HKBU, endeavoured to develop alternative drug options. “loop3” identified as a new therapeutic target Sclerostin suppresses bone formation by antagonising the “Wnt signalling pathway”. The “Wnt signalling pathway” modulates the stem cells responsible for skeletal tissue regeneration. Therefore, inhibition of sclerostin promotes bone growth. The research team discovered that a “loop3 domain” in the core region of sclerostin can be used as a molecular target to inhibit sclerostin. Through genetic studies, it was shown that deficiency of the loop3 domain can inhibit sclerostin’s antagonistic effect against the Wnt signalling pathway, but it does not affect the cardiovascular protective effect of sclerostin. The result suggests that the loop3 domain can serve as a molecular target for inhibiting sclerostin while preserving its cardiovascular protective function. The researchers then proceeded to screen aptamers that can specifically inhibit sclerostin loop3. Aptamers are single-stranded DNA or RNA molecules that can selectively bind to molecular targets such as proteins. After binding with specific proteins, aptamers may inhibit protein–protein interactions and thereby elicit certain therapeutic effects. Through a combinatorial technology, an aptamer “aptscl56” was selected as a potential sclerostin inhibitor that targets the loop3 structure. Aptamer selected as effective and safe sclerostin inhibitor The research team examined aptscl56’s therapeutic functions with osteoporotic rat models and osteogenesis imperfecta mouse models. They found that aptscl56 effectively promots bone formation. On the other hand, the application of aptscl56 does not increase the risk of developing cardiovascular diseases such as aortic aneurysms and atherosclerotic development in both models. The medical use of aptamers confers certain advantages, such as thermal stability and ease of synthesis. However, they are prone to rapid degradation and renal filtration. The research team therefore modified aptscl56 to produce an aptamer named “Apc001” with a longer half-life. The team demonstrated that Apc001 promotes bone formation, increases bone mass, improves bone microarchitecture integrity, and enhances bone mechanical properties in rats with osteoporosis and mice with osteogenesis imperfecta. Clinical trials due to start in 2024 “Searching for reliable and safe alternatives to overcome the limitations of the currently available drugs is crucial to help patients who need bone anabolic therapies. Our ongoing studies, which span from identifying molecular targets for sclerostin inhibition to aptamer drug discovery, offer hope for the development of next-generation sclerostin inhibitors in the near future,” said Professor Zhang Ge. “Our search for alternative drugs for bone anabolic therapies is a good example of tripartite collaboration between academia, industry and the government. The research work was partly conducted in collaboration with a local biotechnology company, and it was supported by the Innovation and Technology Fund. Some biotechnology companies in the Mainland were engaged in certain aspects of developmental research for the aptamer, such as toxicology tests. The collaborative efforts will continue to create more synergy and fruitful results,” said Professor Lyu Aiping. The therapeutic aptamer Apc001 was granted orphan drug designation by the FDA for the treatment of osteogenesis imperfecta in 2019. Contact Details Communication and Public Relations Office, HKBU Christina Wu hkbunews@hkbu.edu.hk
December 19, 2022 09:00 AM Eastern Standard Time
Image
Digital Asset DirectVoyager Life PLC
Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
December 19, 2022 08:10 AM Eastern Standard Time
Video
Digital Asset DirectNuminus Wellness Inc.
Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
December 19, 2022 08:02 AM Eastern Standard Time
Video
News ReleaseCleverTap
CleverTap, the World's #1 Retention Cloud today announced the appointment of Satyadeep Mishra as their new Chief Human Resources Officer. He joins from the hospitality-technology platform, OYO where he worked as the Chief Human Resources Officer for its technology, product, global functions and international markets teams. With over two decades of experience working with the likes of Jio, Barclays and Bajaj Finserv among others, Satya brings with him a demonstrable history of leading teams and conceptualizing innovative HR strategies across domains of talent acquisition, training & development, and performance management. He also played a pivotal role in the transformational growth journey of Jio’s core telecom and digital initiatives. “We are excited to have Satya onboard. Having nurtured some of the industry’s leading experts, quality talent has always been a top priority for CleverTap. And with Satya’s immense experience, I have no doubt that he will lead our People Strategy and continue to build on our culture which puts employees first, as we go from strength to strength in our journey as global MarTech leaders”, said Sidharth Malik, Chief Executive Officer, CleverTap. “It's an absolute pleasure to be part of such a dynamic and exuberant team. The growth of CleverTap over the past few years is a testament to the capabilities and dedication of everybody involved with the team. The roles that HR functions play, not just in people strategy, but even in business, have become significant for more companies, especially within the era of work from anywhere. I am elated to be working with like-minded individuals that understand the importance of retaining and nurturing bright talent. I am confident that together, we can scale new heights and break conventional barriers while creating value not only for our customers but also for our employees the world over”, said Satyadeep Mishra, Chief Human Resource Officer, CleverTap. About CleverTap CleverTap is the World's #1 Retention Cloud that helps app-first brands personalize and optimize all consumer touch points to improve user engagement, retention, and life-time value. It's the only solution built to address the needs of retention and growth teams, with audience analytics, deep-segmentation, multi-channel engagement, product recommendations, and automation in one unified product.The platform is powered by TesseractDB™ - world’s first purpose-built database for customer engagement, offering both speed and economies of scale. CleverTap is trusted by 1500 customers, including Gojek, ShopX, Electronic Arts, TED, English Premier League, TD Bank, Carousell, AirAsia, Papa John’s, and Tesco. Backed by leading investors such as Sequoia India, Tiger Global, Accel, and CDPQ the company is headquartered in Mountain View, California, with presence in San Francisco, New York, São Paulo, Bogota, London, Amsterdam, Sofia, Dubai, Mumbai, Singapore, and Jakarta. For more information, visit clevertap.com or follow on LinkedIn and Twitter. Forward-Looking Statements Some of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction Contact Details Sony Shetty sony@clevertap.com Company Website https://clevertap.com/
December 19, 2022 07:59 AM Eastern Standard Time
Digital Asset DirectSkinBioTherapeutics PLC
Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
December 19, 2022 06:14 AM Eastern Standard Time
Video
News ReleasePatient Safety Authority
The nursing field offers huge career opportunities. But with a critical nursing shortage and new complexities for those entering the profession, how can we ensure the next generation of nurses can handle whatever might come their way? What does it take to successfully transition them from classroom into practice? These are some of the questions addressed in the December issue of PATIENT SAFETY. “We need to prepare our nurses to learn in a new way and adapt how they make decisions, even at the bedside,” says Cedar Crest College senior instructor Eileen Fruchtl, MSN. She explores issues such as simulation technology, testing for decision making, core curricula and the expanding roles of nurses in the article, Onward and Upward: The Future of Nursing Education. “Most people don’t see the complexity of what a nurse does at the bedside, what they have to have in their knowledge base to keep patients safe,” she says. “The core curriculum integrates things that didn’t even exist years ago—like informatics. We see a lot more in politics and advocacy, leadership and management, and communities.” Fruchtl explains that nurses drive the healthcare system through their work in policy making, insurance, education, and in the community. “A lot of students don’t realize the extent of the opportunities they’ll have.” Transitioning students from academia into safe practice is the subject of another article based on a study conducted by faculty at Commonwealth University, Bloomsburg Campus, University of Wisconsin-Milwaukee College of Nursing and Indiana University of Pennsylvania. Their research revealed new nurses’ challenges including lack of skill dexterity, absence of mentors, and imposter syndrome. Enhancing academic curriculum, cooperative efforts between practice nurses and faculty, and improving nurse residency programs can narrow the academic practice gap, the authors conclude. Other topics in this issue of PATIENT SAFETY include: How a peer support program improves care for all – Jefferson Health’s RISE program is a psychological first-aid, peer-support team for distressed healthcare workers and providers in the immediate wake of a stressful or traumatic workplace event. Jefferson’s program leads, John Olsen and Dr. Scott Cowan, explain the program’s genesis, its positive impact, and how it can be replicated in other institutions. An inside look to healthcare in prison – Erica Benning, Bureau of Healthcare director for the Pennsylvania Department of Corrections (PA DOC), discusses healthcare delivery for almost 40,000 incarcerated individuals: what can be done in-house, how her team handles inmates with mental illness, their COVID response, and more. PATIENT SAFETY is the peer-reviewed journal of the Patient Safety Authority. A scientific publication, PATIENT SAFETY humanizes patient harm with stories, opinion pieces, and magazine-quality design. It has a readership of more than 45,000 people in 164 countries. About PSA Established under the Medical Care Availability and Reduction of Error (MCARE) Act of 2002, the PSA, an independent state agency, collects and analyzes patient safety data to improve safety outcomes and help prevent patient harm. http://patientsafety.pa.gov/ Contact Details Bev Volpe +1 609-230-4696 bev@madisongall.com Company Website http://patientsafety.pa.gov/
December 16, 2022 12:52 PM Eastern Standard Time
Image
News ReleaseSyntekabio, Inc.
Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, has launched STB CLOUD worldwide. Running on Syntekabio’s own supercomputing infrastructure, the new AI drug discovery cloud platform is driven by genomic big data and the latest AI technology. It can process small molecule drug discovery on any device, anytime and anywhere. STB CLOUD outperforms common Software as a Service (SaaS) options in the market. By integrating DeepMatcher ®, an AI-driven small molecule drug discovery platform, this new service has automated AI computing function within its own supercomputing hardware environment and database into the cloud system. Improving standardization, simplification and automation of the existing computer-aided drug discovery (CADD) process optimizes the drug discovery and development process far better in terms of time, cost, accuracy and resources. It generates a comprehensive automatic report, including active substance candidates with users’ minimum input, for instance, only by inputting the name of the target protein related to a disease of interest. “We live in a rapidly changing world with constant disruptions by new and advanced technologies. STB CLOUD is an instant game changer for faster, easier and more accurate drug discovery. Investing in technologies like this further supports clinical trials critical for making lifesaving drugs in a timely manner,” said the CEO of Syntekabio, Jongsun Jung, Ph.D. “This landmark achievement will undoubtedly strengthen Syntekabio’s position in the competitive AI drug discovery industry. Bringing STB CLOUD to the global marketplace has been a tremendous endeavor by our exceptional scientists and engineers.” For the evaluation of automated drug discovery performance in STB CLOUD, DeepMatcher ® was used for 10 target proteins with a library of 120 million compounds available for quick purchase. The evaluation included compounds with known binding affinity as positive controls in the compound library and tracked the number of positive controls recovered during the DeepMatcher ® process, which is comprised of three steps: 3D screening, optimal pose and validation. After the first step, the average recovery rate was 31 percent among 1,000 top-ranked candidates. At the completion of the final validation step (MD simulation), the recovery rate resulted in an average of 16 percent among 200 final-ranked candidates for 10 targets. These outstanding results prove not only the power of STB CLOUD but the potential of DeepMatcher ® itself in the overall drug discovery industry. Syntekabio is already working on further strengthening STB CLOUD, with a neoantigen prediction platform (NEO-ARS™) and a multivariate biomarker prediction and discovery platform (PGM-ARS™), to be used for supporting clinical trials with a selection of patients in the near future. Additionally, the company’s new high-performance supercomputing center with 10,000 CPU/GPU computing servers is underway to be completed in the first half of 2023. For business development meetings and information about Syntekabio’s products and services, contact the New York office at +1 (212) 371-2544 or admin@syntekabiousa.com. More information about STB CLOUD is available at cloud.syntekabio.com. SyntekaBio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at www.syntekabio.com. Contact Details Syntekabio USA | WMSG Sabina Lee +1 201-408-5342 wgroup@wmedical.org Company Website https://www.syntekabio.com/eng
December 16, 2022 11:00 AM Eastern Standard Time
Contact Us
Pricing
About us
Features
News Hub
Terms of Use
Privacy Policy